Newsroom | 4859 results

DUBLIN--(BUSINESS WIRE)--The "Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends - Forecast up to 2030" has been added to ResearchAndMarkets.com's offering. As of 2024, the global cone rod dystrophy market was valued at USD 131.29 million and is anticipated to reach USD 177.59 million by 2030. This growth, at a projected CAGR of 5.33% from 2025 to 2030, is underpinned by increasing awareness of genetic disorders and a rising need for effective...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company’s common stock to 13 new employees (t...

ANN ARBOR, Mich.--(BUSINESS WIRE)--OcuSciences, Inc., a leader in advanced ocular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its flagship device, the OcuMet Beacon, proprietary, non-invasive tool for assessing retinal health. The indication for use of the OcuMet Beacon is a confocal scanning ophthalmoscope indicated for infrared (IR) and autofluorescence (AF) imaging of a human retina with or without the use of a mydriatic agent. The...

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company, announces that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting taking place from May 4 to 8 in Salt Lake City, UT. These posters present clinical data related to the STAR Study, Sydnexis’ groundbreaking pivotal phase 3 clinical trial evaluating SYD-101, a novel and proprietary l...

BOSTON--(BUSINESS WIRE)--Leading global ophthalmology CRO Ora announces participation in ARVO 2025, including 2 podium presentations and 10 accepted posters...

OTTAWA, Ontario--(BUSINESS WIRE)--The Canadian Association of Optometrists releases a new “GetEyeWise” public campaign to raise awareness about eye health....

OTTAWA, Ontario--(BUSINESS WIRE)--À l'occasion du Mois de la santé visuelle, l'Association canadienne des optométristes (ACO) s'engage à sensibiliser la population à la santé oculaire et aux soins de la vue. Avec le vieillissement de la population, l'intensification des activités nécessitant une vision rapprochée et l'épidémie croissante de myopie juvénile, intégrer les soins de la vue dans les routines de soins de santé est crucial pour tous les groupes d'âge, des tout-petits aux personnes âgé...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is performing well, and we remain focused on positioning the company for long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We’re making meaningful progress in our journey to significantly enhance the standard of care...

比利時根特--(BUSINESS WIRE)--(美國商業資訊)-- 致力於開創視力未來的醫療科技公司Azalea (A-zuh-lay-ah) Vision今日宣布，其1500萬歐元A輪融資已完成首次交割，成功籌集900萬歐元。同時，公司任命Robert J. Dempsey為董事長，以指導公司在歐洲和美國市場的策略發展。 Azalea Vision執行長Enrique Vega表示：「在這一A輪融資里程碑中，重複投資人的踴躍參與再次證明了他們對我們的醫療器材以及為推動智慧眼部健康未來所展開創新的信任。在本輪融資中，來自SPRIM Global Investments和Afrimobility以及一家未公開的策略投資人的額外資金進一步彰顯了對我們平台的信心。Robert J. Dempsey在眼科領域是備受尊敬的領導者，他的任命為公司帶來了深厚的領域專業知識和強大的產業人脈關係，將在我們邁向下一階段成長之際指導我們的領導團隊。」 Robert J. Dempsey表示：「我相信，一個擁有智慧、互聯且能輕鬆自我調整的視力的未來，是當今眼科醫療器材創新中最令人振奮的尖端領域之一。我很榮幸...